The HHS said center directors deserve to be supported by managers aligned with aggressive goals “to expeditiously advance ...

Parataxis is launching a Bitcoin treasury platform for South Korean institutional investors, which saw Bridge Bio’s stock ...

However, RBC Capital has reiterated that Vertex could require stronger execution to adopt Alyftrek to justify the current ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin” or the "Company”), a late-stage pharmaceutical company with a broad ...

Zealand Pharma A/S’s shares have slid to a near 18-month low, as the Danish biotech’s experimental weight-loss drug faces mounting competition and a long wait ahead for crucial trial results.

The biotech sector has underperformed the overall market. Those are sentiments echoed by JPMorgan analyst Chris Schott, given ...

On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the agency unveiled a pilot ...

The biotech firm filed its IPO paperwork May 23 in a bid to boost its finances, noting there was "substantial doubt" about ...

The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite ...

Sanofi paid a more than 300% premium on its acquisition of Vigil Neuroscience, suggesting a fierce battle to seal the deal.

In the volatile biotech industry, it is easy to overlook small-cap medical device companies, particularly those that are not ...

Boston-based Verve is a rare example of a gene editing company targeting a disease that affects a large population, offering ...